top of page
hero 4.png
Exosomica logo

 
Advanced therapies against
neurodegenerative diseases

OBJECTIVES

Advanced therapies against neurodegenerative diseases

Parkinson’s disease is the second most common neurodegenerative disorder affecting millions of people worldwide. Disease is characterized by a progressive degeneration of dopaminergic neurons in substantia nigra and striatum and also by accumulations of defective α-synuclein protein.

OUR TEAM

Meet the scientific minds behind Exosomica

Dr. Augustas Pivoriūnas is Head of the Department of Stem Cell Biology at the State Research Institute Centre for Innovative Medicine. He leads an active group of scientists and PhD students and his research interests focus primarily on extracellular vesicles (EVs) derived from different types of adult stem cells and their applications in basic research and regenerative therapies. Dr. Augustas Pivoriūnas is co-founder and President of the Lithuanian Association of Stem Cell Researchers, he is also a co-founder and treasurer of Baltic Society of Extracellular Vesicles. Dr. Augustas Pivoriūnas is a co-founder and shareholder of the joint stock company Exosomica.

R&D Lead
Co-founder of Exosomica

Dr. Augustas
Pivoriunas

Arunas Zebrauskas has 5+ years of experience as Head of Project Management department at State Research Institute Centre for Innovative Medicine in Vilnius. In the past he worked in Vilnius University Hospital Zalgirio Clinics, pharmaceutical companies, consulting companies. Currently Arunas is a PhD student in biology in Vytautas Magnum University. He holds a medical doctor degree from Vilnius University Medical Faculty, Master’s degree in public health from Utrecht university / Masaryk university. His main fields of interests are: advanced therapy medicinal products (ATMPs) regulation, patient safety, management of public health, management of science.

Arunas Zebrauskas

Business Development Lead
Co-founder of Exosomica

Arunas
Zebrauskas

Laurynas has a background of communication sciences with a specialty of business information management. He has 10+ years of experience in R&D project management, innovation development in the field of life sciences.

Laurynas Zemaitaitis

CEO 
/

Laurynas
Zemaitaitis

Agne is a PhD student at the Center for Innovative Medicine, her work topic is: In vitro modeling of blood-brain barrier damage accompanying neurological disorders. Agne Pociute is responsible for conducting experiments: management of bioreactors, cultivation of stem cells, development of a technological process for the production of exosomes.

Agne Pociute

Researcher biotechnologist
/

Agne
Pociute
INNOVATION

Use of extracellular vesicles (exosomes) as a therapeutic tools

Our scientists for the first time demonstrated that intranasal administration of EVs derived from human dental pulp stem cells improve motor and cognitive functions in the rat model of Parkinson's disease.

The ultimate goal is to create patented technology for production, isolation and application of exosomes as a minimally invasive therapeutic tools against wide spectrum of neurological disorders.

We are developing technology allowing scaling up production and isolation of therapeutically active exosomes.

At Exosomica, we are transforming the landscape of Parkinson's disease treatment through the development of our cutting-edge exosome therapies

ABOUT

Advantages of the use of the extracellular vesicles (exosomes) as therapeutic tools over cells for Parkinson's disease.

CONTACT

Contact us for more information about our innovation in the use of exosomes, or if you need to speak to a member of our team.

hero 4.png
hero 4.png
Exosomica logo

Advanced therapies against neurodegenerative diseases

bottom of page